Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mephedrone + methcathinone is an illicit combination of two synthetic stimulant drugs from the cathinone chemical class. Mephedrone (4-methylmethcathinone) is known for its entactogenic and stimulant effects, acting as a non-selective monoamine uptake inhibitor and releaser at dopamine, serotonin, and norepinephrine transporters, with additional affinity for 5-HT2A and α-adrenergic receptors[1][2][3]. Methcathinone is a closely related stimulant, structurally similar to both mephedrone and cathinone itself, with primary action as a dopamine and norepinephrine releasing agent. The combination is used recreationally for its strong stimulant and empathogenic effects but carries elevated risks of harmful cardiovascular and neuropsychiatric effects, including increased risk of heart strain, serotonin syndrome, and seizures. Both substances are controlled in most jurisdictions, and their combination significantly increases the danger of acute toxicity[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mephedrone + methcathinone.